Monitoring treatment harm in myalgic encephalomyelitis/chronic fatigue syndrome: A freedom-of-information study of National Health Service specialist centres in England. — CFSMEATLAS
Monitoring treatment harm in myalgic encephalomyelitis/chronic fatigue syndrome: A freedom-of-information study of National Health Service specialist centres in England.
McPhee, Graham, Baldwin, Adrian, Kindlon, Tom et al. · Journal of health psychology · 2021 · DOI
Quick Summary
This study looked at how 38 ME/CFS specialist clinics in England monitor and report harms from treatments like graded exercise therapy and cognitive behavioural therapy. Researchers found that clinics were inconsistent in how they handle treatment-related harm, rarely warned patients about potential risks in their written materials, and reported zero cases of harm despite knowing many patients dropped out of treatment. The study suggests clinics need better systems to detect, record, and stop treatments when patients are being harmed.
Why It Matters
This research directly addresses patient concerns about treatment safety in ME/CFS, particularly regarding graded exercise therapy, which many patients report has worsened their condition. The findings reveal a critical disconnect between patient experiences of harm and clinic reporting systems, highlighting a patient safety gap in NHS ME/CFS services. Understanding these monitoring failures is essential for developing safer treatment protocols and ensuring patient voices about harm are heard and recorded.
Observed Findings
NHS specialist clinics in England showed highly inconsistent approaches to identifying and managing treatment-related harms.
Written patient information materials from clinics contained little to no warning about potential treatment-related harms.
No clinic reported any cases of treatment-related harm despite acknowledging that many patients discontinued treatment.
38 of 57 clinics surveyed provided usable data for analysis.
Inferred Conclusions
Current NHS ME/CFS clinics lack standardized protocols for anticipating, detecting, and recording treatment-related harms.
Clinic communication to patients about treatment risks is inadequate and inconsistent across England.
Systematic underreporting of harm may be occurring due to insufficient monitoring infrastructure rather than actual absence of harm.
Immediate policy changes are needed to develop standardized harm surveillance and patient safety systems.
Remaining Questions
What is the actual prevalence and severity of treatment-related harms in ME/CFS patients receiving these therapies?
Why are clinics not detecting or reporting harms—is it due to inadequate monitoring, lack of training, or organizational barriers?
What This Study Does Not Prove
This study does not establish whether graded exercise therapy or cognitive behavioural therapy actually cause harm—it documents that clinics are not systematically detecting or reporting such harms if they occur. The zero harm reports may reflect underdetection rather than absence of harm. The study also cannot determine harm rates or severity, as it assesses monitoring systems rather than directly measuring patient outcomes.